|
|
Product Name: Nilotinib
Generic Name: Nilotinib
Common Brands: Tasigna
Pharmaceutical Categories: Cancer
Where to buy Nilotinib online:
| Shop | Product | Forms | Strength | Conditions |
| MEDS FOR SALE | | Tasigna capsules 200 mg | 5% discount coupon: 5OFFPayment: Visa, Mastercard, AmEx, Bitcoin, Tether (USDT)Shipping: worldwideDelivery: unregistered mail, trackable courier |
Nilotinib (trade names include Tasigna, Tasinga, Nilotib) is an anti cancer medication from protein kinase inhibitors pharmacological group. This medicine is used for the treatment of Philadelphia chromosome (Ph+)-positive chronic myelogenous leukaemia. It is also in research phases for the therapy of Parkinson's disease, Alzheimer's disease, Amyotrophic lateral sclerosis, dementia, Huntington's disease, gastrointestinal stromal tumor. It works by inhibiting various enzymes called kinases.
Customers also buy these medications from the same pharmacological classes:
Abemaciclib (Verzenio, Verzenios)
Abiraterone (Zytiga)
Anastrozole (Arimidex)
Axitinib (Inlyta)
Bosutinib (Bosulif)
Brigatinib (Alunbrig)
Encorafenib (Braftovi)
Exemestane (Exemestan)
Gefitinib (Iressa)
Ibrutinib (Imbruvica)
Imatinib (Gleevec)
Larotrectinib (Vitrakvi)
Letrozole (Femara)
Melphalan (Alkeran)
Nintedanib (Ofev, Vargatef)
Olmutinib (Olita)
Pazopanib (Votrient)
Ponatinib (Iclusig)
Regorafenib (Stivarga)
Ribociclib (Kisqali)
Rociletinib (Xegafri)
Sorafenib (Nexavar)
Tivozanib (Fotivda)
Pharmaceutical and medical classifications:
Anti cancer drugs
Antineoplastic medicines
Oncological treatment
Leukaemia therapy
The Anatomical Therapeutic Chemical (ATC) classification system (developed by the World Health Organization):
L - Antineoplastic and immunomodulating agents
L01 - Antineoplastic agents
L01X - Other antineoplastic agents
L01XE - Protein kinase inhibitors
L01XE08 - Nilotinib
Medical conditions for estrogens conjugated in the International Statistical Classification of Diseases and Related Health Problems:
Malignant neoplasm of other connective and soft tissue - C49
Gastrointestinal stromal tumor, unspecified site - C49.A0
Myeloid leukemia - C92
Mental disorders due to known physiological conditions - F01-F09
Huntington's disease - G10
Spinal muscular atrophy and related syndromes - G12
Amyotrophic lateral sclerosis - G12.21
Parkinson's disease - G20
Alzheimer's disease - G30
Pregnancy category:
D - Australia
D - United States (Positive evidence of risk)
Forms of active pharmaceutical ingredients (APIs):
Nilotinib Base
Nilotinib Hydrochloride
Nilotinib Hydrochloride Dihydrate
Nilotinib Hydrochloride Monohydrate
Chemical, international, and other names of this drug:
AMN107
Nilotinib HCl
Nilotinibe
Nilotinibi
Nilotinibum
Nilotynib
Most known trade names (brands and generics) worldwide:
Tasigna - Novartis
Tasinga - Novartis
Nilotib - Caprane Pharmaceutical
Nilotinib - Actiza Pharmaceutical
References and external sources:
Nilotinib main article on Wikipedia: https://en.wikipedia.org/wiki/Nilotinib
Nilotinib compound on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/Nilotinib
Nilotinib Hydrochloride compound on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/Nilotinib-hydrochloride
Nilotinib Hydrochloride Monohydrate compound on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/16757572
Nilotinib Hydrochloride Dihydrate compound on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/Nilotinib-hydrochloride-dihydrate
Nilotinib medicine on DrugBank: https://www.drugbank.ca/drugs/DB04868
Nilotinib Hydrochloride Monohydrate on DrugBank: https://www.drugbank.ca/salts/DBSALT001325
Nilotinib FAQ on MedlinePlus (revised 12/15/2021): https://medlineplus.gov/druginfo/meds/a608002.html
Nilotinib information on the U.S. National Cancer Institute (revised December 30, 2020): https://www.cancer.gov/about-cancer/treatment/drugs/nilotinib
Tasigna (Nilotinib) capsules drug label on DailyMed (revised February 15, 2022): https://dailymed.nlm.nih.gov/dailymed/lookup...
Tasigna (Nilotinib) 150 mg, 200 mg capsules official website for U.S. residents only: https://www.us.tasigna.com/
Tasigna (Nilotinib) official website for non-U.S. residents powered by Novartis: http://www.tasigna.com/
Tasigna (Nilotinib) capsules official prescribing information and medication guide from the U.S. FDA (revised 12/2020): https://www.accessdata.fda.gov/drugsatfda_docs/label...
Tasigna (Nilotinib) capsules for oral use prescribing information and medication guide on Novartis pharmaceutical company website (revised 09/2021): https://www.novartis.us/sites/www.novartis.us/files/tasigna...
Tasigna (Nilotinib) 150 mg hard capsules patient information leaflet on Medicines.org.uk (revised November 2020): https://www.medicines.org.uk/emc/files/pil.5852.pdf
Tasigna (Nilotinib) 200 mg hard capsules patient information leaflet on Medicines.org.uk (revised November 2020): https://www.medicines.org.uk/emc/files/pil.6251.pdf
Revised: April 2022
|
Disclaimer: Please note, this website is not an online pharmacy, drugstore and related online pharma shop. It does not sell, supply or advertise any prescription and OTC drugs, medications, other goods and services. All reviews, links, lists, databases, texts, videos, images, and other content on the website are provided free and only for informational and educational purposes. Medical content on this website, including drug names, indications, contraindication, side effects, categories, classifications, forms, doses, prices, other health and pharmaceutical information are taken only from trusted and authoritative professional sources (see "References"), reviewed and prepared by our licensed experts, content inspectors and editors.
You should always consult your doctor or other healthcare professional before using any medication. This website, our staff and support do not provide own medical instructions and advices.
All brands and trade names appearing on the website are registered trademarks and intellectual property of their respective companies.
Remember that buying drugs and medicines online is a responsibility only of customers, sellers and suppliers regarding existing legislation in their jurisdictions.
|
|